AtriCure Inc (ATRC) - Total Liabilities
Based on the latest financial reports, AtriCure Inc (ATRC) has total liabilities worth $160.21 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of AtriCure Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
AtriCure Inc - Total Liabilities Trend (2001–2025)
This chart illustrates how AtriCure Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AtriCure Inc asset portfolio.
AtriCure Inc Competitors by Total Liabilities
The table below lists competitors of AtriCure Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Imerys SA
PA:NK
|
France | €3.25 Billion |
|
Ahlatci Dogal Gaz Dagitim Enerji ve Yatirim A.S.
IS:AHGAZ
|
Turkey | TL163.86 Billion |
|
China Railway Materials Co Ltd
SHE:000927
|
China | CN¥10.05 Billion |
|
Shanghai Huafon Aluminium Corp
SHG:601702
|
China | CN¥3.49 Billion |
|
Grupo Mateus S.A
SA:GMAT3
|
Brazil | R$12.74 Billion |
|
Metcash Ltd
AU:MTS
|
Australia | AU$5.51 Billion |
|
BitVentures Limited
NASDAQ:BVC
|
USA | $23.99K |
|
Basic Fit NV
AS:BFIT
|
Netherlands | €3.44 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down AtriCure Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AtriCure Inc (ATRC) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AtriCure Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AtriCure Inc (2001–2025)
The table below shows the annual total liabilities of AtriCure Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $162.24 Million | +9.36% |
| 2024-12-31 | $148.36 Million | +0.40% |
| 2023-12-31 | $147.76 Million | +14.82% |
| 2022-12-31 | $128.69 Million | -2.18% |
| 2021-12-31 | $131.56 Million | -56.46% |
| 2020-12-31 | $302.14 Million | -2.70% |
| 2019-12-31 | $310.54 Million | +189.20% |
| 2018-12-31 | $107.38 Million | +0.79% |
| 2017-12-31 | $106.54 Million | -1.33% |
| 2016-12-31 | $107.98 Million | +24.97% |
| 2015-12-31 | $86.41 Million | +234.06% |
| 2014-12-31 | $25.87 Million | -34.26% |
| 2013-12-31 | $39.34 Million | +97.40% |
| 2012-12-31 | $19.93 Million | +9.25% |
| 2011-12-31 | $18.24 Million | +7.45% |
| 2010-12-31 | $16.98 Million | -5.10% |
| 2009-12-31 | $17.89 Million | +25.56% |
| 2008-12-31 | $14.25 Million | +44.89% |
| 2007-12-31 | $9.83 Million | +16.61% |
| 2006-12-31 | $8.43 Million | +23.00% |
| 2005-12-31 | $6.86 Million | -82.88% |
| 2004-12-31 | $40.06 Million | +18.89% |
| 2003-12-31 | $33.70 Million | +5853.36% |
| 2002-12-31 | $566.00K | +76.88% |
| 2001-12-31 | $320.00K | -- |
About AtriCure Inc
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; m… Read more